Seurer Jerad G. reported grant involving 257,000 derivative units of InMed Pharmaceuticals Inc. at $0.00 for $0 on Nov 9, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
See Remarks
See Remarks
Filed Nov 12, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
257,000Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
257,000Direct
Trade date
Nov 9, 2026Grant
Filed
Nov 12, 2026, 4:30 PM ET3-day reporting delay
Accession
0001193125-26-458560Code A · Transaction 399084
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

MTRI price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MTRI · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 19, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: This option represents the right to purchase 257,000 shares of the Issuer's common stock and will vest as to 25% on November 9, 2027 and in equal monthly installments thereafter through November 9, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.